Update on nonserous ovarian cancer trials

Annals of Oncology

Volumn 24, Issue SUPPL.10, 2013, Pages

  Fujiwara, K ^a   Yoshida, H ^a   Hasegawa, K ^a  

^a SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; EVEROLIMUS; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NINTEDANIB; OXALIPLATIN; PACLITAXEL; SUNITINIB; TEMSIROLIMUS; TOPOTECAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; HUMAN; MULTIPLE CYCLE TREATMENT; OVARY ADENOCARCINOMA; OVARY MUCINOUS ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA, MUCINOUS; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INDOLES; MOLECULAR TARGETED THERAPY; OVARIAN NEOPLASMS; TOR SERINE-THREONINE KINASES;

EID: 84888257588     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt470     Document Type: Article

References (8)

1. Winter WE, III, Maxwell GL, Tian C et al. Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 3621-3627.
2. Mackay HJ, Brady MF, Oza AM et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Int J Gynecol Cancer 2010; 20: 945-952.
3. Sugiyama T, Kamura T, Kigawa J et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589.
4. Takakura S, Takano M, Takahashi F et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer 2010; 20: 240-247.
5. Mabuchi S, Kawase C, Altomare DA et al. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res 2009; 15: 5404-5413.
6. Miyazawa M, Yasuda M, Fujita M et al. Therapeutic strategy targeting the mTORHIF- 1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int 2009; 59: 19-27.
7. Hess V, A'Hern R, Nasiri N et al. Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment. J Clin Oncol 2004; 22: 1040-1044.
8. Marquez RT, Baggerly KA, Patterson AP et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res 2005; 11: 116-6126.